You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-L1

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NSCLC Trial in Wuhan (Cadonilimab, Pemetrexed, Carboplatin)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Wuhan, Hubei, China
    Qian Chu
Aug 18, 2023

Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)

Not yet recruiting
  • Metastatic Pancreatic Cancer
  • Durvalumab
  • Rintatolimod
  • Rotterdam, Zuid-Holland, Netherlands
    Erasmus MC
Jun 23, 2023

Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS=1) Trial (SG001 injection, Paclitaxel, Cisplatin)

Not yet recruiting
  • Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
  • SG001 injection
  • +5 more
  • (no location specified)
Jan 27, 2023

Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC Trial run by the NCI (N-803, Pembrolizumab, PD-L1 t-haNK)

Recruiting
  • Gastroesophageal Junction (GEJ) Cancers
  • Advanced HNSCC
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2023

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

NSCLC Stage IV Trial in Netherlands (18F-PD-L1)

Recruiting
  • NSCLC Stage IV
  • 18F-PD-L1
  • Amersfoort, Netherlands
  • +7 more
Nov 7, 2022

Head and Neck Squamous Cell Carcinoma Trial (Zanzalintinib, Zanzalintinib-matched Placebo, Pembrolizumab)

Not yet recruiting
  • Head and Neck Squamous Cell Carcinoma
  • (no location specified)
Oct 9, 2023

NSCLC Trial (PM8002, Placebo, Carboplatin)

Not yet recruiting
  • NSCLC
  • (no location specified)
Feb 23, 2023

Head and Neck Squamous Cell Carcinoma, Magnetic Resonance Imaging, Neoadjuvant Therapy Trial in Guangzhou

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
    • Guangzhou, Guangdong, China
      Sun Yat-sen Memorial Hospital
    Jul 27, 2023

    Programmed Death Ligand-1 in Nasopharyngeal and Hyypopharyngeal

    Not yet recruiting
    • Nasopharyngeal and Hypopharyngeal Carcinoma
    • immunohistochemical
    • Sohag, Egypt
      Sohag University Hospital
    Oct 23, 2022

    Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Unresectable Breast Carcinoma Trial in Aurora (Nab-paclitaxel,

    Withdrawn
    • Triple Negative Breast Cancer
    • +4 more
    • Aurora, Colorado
      University of Colorado Hospital
    Dec 2, 2022

    Breast Cancer Trial (RO7247669, Pembrolizumab, Nab-Paclitaxel)

    Not yet recruiting
    • Breast Cancer
    • (no location specified)
    May 2, 2023

    Advanced Solid Tumor Trial (HLX43)

    Not yet recruiting
    • Advanced Solid Tumor
    • (no location specified)
    Oct 30, 2023

    Esophageal Squamous Cell Carcinoma Trial (Paclitaxel, Irinotecan, Pembrolizumab)

    Recruiting
    • Esophageal Squamous Cell Carcinoma
    • Chuo-ku, Tokyo, Japan
      National Cancer Center Hospital ( Site 3700)
    Jan 31, 2023

    Efficacy, Safety Trial (PD-L1 inhibitor)

    Not yet recruiting
    • Efficacy
    • Safety
    • PD-L1 inhibitor
    • (no location specified)
    Apr 6, 2022

    Non Small Cell Lung Cancer Trial in Pittsburgh (Fecal Microbiota Transplant (FMT), Pembrolizumab)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • Pittsburgh, Pennsylvania
      UPMC Hillman Cancer Center
    Dec 20, 2022

    Gastrointestinal Tumors Trial in Beijing (68Ga-WL12 PET/CT)

    Recruiting
    • Gastrointestinal Tumors
    • 68Ga-WL12 PET/CT
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Jul 18, 2022

    Advanced NSCLC Trial (BNT116, Cemiplimab)

    Not yet recruiting
    • Advanced Non-Small Cell Lung Cancer
    • (no location specified)
    Jan 3, 2023

    Contribution of Fractional Exhaled Nitric Oxide asPrognostic

    Not yet recruiting
    • Metastatic Non-small Cell Lung Cancer
    • Measurement of FeNO
    • Dijon, France
      Chu Dijon Bourgogne
    Aug 8, 2023

    Solid Tumor, Lung Cancer Trial in Beijing (18F-WL12 PET or 68Ga-WL12 PET)

    Recruiting
    • Solid Tumor
    • Lung Cancer
    • 18F-WL12 PET or 68Ga-WL12 PET
    • Beijing, China
      Shunlian Zhou
    Jul 18, 2022

    Lung Cancer Trial (QL1706, Tilesizumab)

    Not yet recruiting
    • Lung Cancer
    • (no location specified)
    Jan 10, 2023

    Anti-angiogenesis Combined With PD-1/PD-L1 Therapy in Advanced

    Not yet recruiting
    • Carcinoma, Hepatocellular
      • (no location specified)
      May 16, 2022

      Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced

      Recruiting
      • Esophageal Neoplasms
      • an anti-PD-1/PD-L1 antibody plus an angiogenesis inhibitor
      • Zhengzhou, Henan, China
        The First Affiliated Hospital of Zhengzhou University
      Apr 21, 2022

      Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

      Recruiting
      • Advanced Solid Tumor
      • Refractory Tumor
      • Radiotherapy
      • +4 more
      • Suzhou, China
        The Second Affiliated Hospital of SchoowUniversity
      Sep 14, 2023

      Efficacy of Immunotherapy in Hepatocellular Carcinoma

      Recruiting
      • Hepatocellular Carcinoma
      • CTC PD-L1, exosomal PD-L1, and exosomal LAG-3 detection
      • Wuhan, Hubei, China
        Zhongnan Hospital of Wuhan University
      Oct 20, 2022